Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial.
Acute kidney injury (AKI)
Anemia
Death
Dialysis
Erythropoietin (EPO)
Hemoglobin
Randomized pragmatic clinical trial
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
13 03 2022
13 03 2022
Historique:
received:
04
01
2022
accepted:
08
03
2022
entrez:
13
3
2022
pubmed:
14
3
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury. This is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin < 11 g/dL and acute kidney injury defined as an increase of serum creatinine of ≥ 0.3 mg/dL within 48 h or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n = 67) and the second received standard of care (control; n = 67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis. There was no statistically significant difference in transfusion need (RR = 1.05, 95%CI 0.65,1.68; p = 0.855), in renal recovery full or partial (RR = 0.96, 95%CI 0.81,1.15; p = 0.671), in need for dialysis (RR = 11.00, 95%CI 0.62, 195.08; p = 0.102) or in death (RR = 1.43, 95%CI 0.58,3.53; p = 0.440) between the erythropoietin and the control group. Erythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia. The trial was registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).
Sections du résumé
BACKGROUND
Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury.
METHODS
This is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin < 11 g/dL and acute kidney injury defined as an increase of serum creatinine of ≥ 0.3 mg/dL within 48 h or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n = 67) and the second received standard of care (control; n = 67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis.
RESULTS
There was no statistically significant difference in transfusion need (RR = 1.05, 95%CI 0.65,1.68; p = 0.855), in renal recovery full or partial (RR = 0.96, 95%CI 0.81,1.15; p = 0.671), in need for dialysis (RR = 11.00, 95%CI 0.62, 195.08; p = 0.102) or in death (RR = 1.43, 95%CI 0.58,3.53; p = 0.440) between the erythropoietin and the control group.
CONCLUSIONS
Erythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia. The trial was registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).
Identifiants
pubmed: 35279078
doi: 10.1186/s12882-022-02727-5
pii: 10.1186/s12882-022-02727-5
pmc: PMC8917943
doi:
Substances chimiques
Hemoglobins
0
Recombinant Proteins
0
Erythropoietin
11096-26-7
Banques de données
ClinicalTrials.gov
['NCT03401710']
Types de publication
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Informations de copyright
© 2022. The Author(s).
Références
Clin Kidney J. 2013 Feb;6(1):8-14
pubmed: 27818745
Kidney Int. 2006 Feb;69(3):560-4
pubmed: 16395253
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
J Cardiovasc Pharmacol. 2015 Jun;65(6):593-600
pubmed: 26065644
Kidney Int. 1993 Nov;44(5):1149-62
pubmed: 8264149
Crit Care. 2006;10(5):R140
pubmed: 17002795
N Engl J Med. 2007 Sep 6;357(10):965-76
pubmed: 17804841
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
pubmed: 23744003
Pediatr Nephrol. 2009 May;24(5):1061-4
pubmed: 19085014
Anesthesiology. 2014 Sep;121(3):582-90
pubmed: 25225746
Clin Nephrol. 2013 Mar;79(3):221-8
pubmed: 23253902
Acta Haematol. 2019;142(1):44-50
pubmed: 30970355
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
Ann Intern Med. 1989 Dec 15;111(12):992-1000
pubmed: 2688507
Ren Fail. 1994;16(1):125-31
pubmed: 8184139
Ann Thorac Surg. 2016 Feb;101(2):690-6
pubmed: 26576750
J Transl Int Med. 2015 Jun-Sep;3(3):93-105
pubmed: 27847896
JAMA. 2002 Dec 11;288(22):2827-35
pubmed: 12472324
Kidney Int. 2006 May;69(10):1806-13
pubmed: 16598197
Nephrology (Carlton). 2016 Aug;21(8):693-9
pubmed: 26479890
Acta Anaesthesiol Scand. 2019 Feb;63(2):200-207
pubmed: 30132785
Nephron Exp Nephrol. 2010;114(2):e69-81
pubmed: 19907192
Crit Care. 2013 Oct 24;17(5):R254
pubmed: 24156702
Am J Nephrol. 2009;30(3):253-60
pubmed: 19494484
Am J Kidney Dis. 2005 Nov;46(5):791-8
pubmed: 16253718
Nephrology (Carlton). 2016 Apr;21(4):295-300
pubmed: 26370061
Am J Kidney Dis. 2005 Nov;46(5):967-9
pubmed: 16253740
J Korean Med Sci. 2012 May;27(5):506-11
pubmed: 22563215
Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F501-F516
pubmed: 29187371
Can J Anaesth. 2018 Jan;65(1):46-59
pubmed: 29098634
Cardiorenal Med. 2015 Feb;5(1):40-7
pubmed: 25759699
Nephrology (Carlton). 2018 Jul;23(7):653-660
pubmed: 28444694
Clin Kidney J. 2019 Jun 17;13(3):413-420
pubmed: 32699621